drugset / Trial / NCT05728658
The Study of ICP-248 in Patients With Mature B-cell Malignancies
Non-randomizedSingle-groupSingle-blindTreatment
Summary
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination Therapy in Patients with Mature B-cell Malignancies.This study consists of two parts: Part 1 dose-finding period and Part 2 dose expansion period.
Timeline
- Start
- 2023-03-09
- Primary completion
- 2025-08-30
- Completion
- 2026-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ICP-248 | Unknown | — | Oral |
| Subject | Orelabrutinib | Small molecule | 150 mg | — |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |